These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

934 related articles for article (PubMed ID: 26027741)

  • 1. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.
    Bignucolo A; De Mattia E; Cecchin E; Roncato R; Toffoli G
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28708103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy.
    De Mattia E; Bignucolo A; Toffoli G; Cecchin E
    Curr Med Chem; 2020; 27(25):4249-4273. PubMed ID: 31298142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
    Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
    Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.
    Katsila T; Juliachs M; Gregori J; Macarulla T; Villarreal L; Bardelli A; Torrance C; Elez E; Tabernero J; Villanueva J
    Clin Cancer Res; 2014 Dec; 20(24):6346-56. PubMed ID: 25324142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.
    Rodríguez J; Viúdez A; Ponz-Sarvisé M; Gil-Aldea I; Chopitea A; García-Foncillas J; Gil-Bazo I
    Crit Rev Oncol Hematol; 2010 Jun; 74(3):193-202. PubMed ID: 19700342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent developments of pharmacogenomics in the treatment of colorectal cancers].
    Astier A
    Ann Pharm Fr; 2010 Jul; 68(4):233-53. PubMed ID: 20637356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
    Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
    Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.